This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The company’s EBITDA margin remained resilient above 20%
Subscribe To Our Newsletter & Stay Updated